Clareo Health | Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
National Cancer Institute (NCI)
University of Medicine and Dentistry of New Jersey
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC.
Potentially completely resectable hepatic metastases without current evidence of other metastatic disease.
Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to registration. (MRI of abdomen may be substituted for CT of abdomen.)
Lab values within 14 days prior to registration:
WBC ≥ 3.0 K/ul
ANC \>1.5 K/ul
Platelets ≥ 100 K/ul
Total bilirubin ≤ 1.5 mg/dl.
Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study.
KPS ≥ 60%
Signed informed consent.
You may not be if
Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.)
